Agendia to Deliver Robust Suite of Data Advancing Breast Cancer Care at ASCO 2022
Company showcases pipeline developments and sub-studies from the revolutionary FLEX Read More
Agendia Appoints Farida Peters-Abbadi as Vice President of Marketing
Strategic hire underscores commitment to commercial growth across genomic assay Read More
Agendia Appoints Elizabeth Hanna as Executive Vice President and Chief Commercial Officer, Bolsters Company’s Global Market Growth Strategy
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – March 15, 2022 Read More
GenomeWeb – Agendia Offering AI-Enabled Genomic Test for Breast Cancer in Brazil as it Eyes Global Market
January 27, 2022 By Leo O’Connor NEW YORK ─ As part Read More
Agendia Study Demonstrates MammaPrint® and BluePrint® Capture Full Spectrum of Early Breast Cancer Biology, Providing Opportunity for Highly Individualized Treatment
New analysis in peer-reviewed journal Genes, Chromosomes and Cancer Read More
Agendia stärkt patientennahe Brustkrebs-Versorgung in Deutschland durch Kooperation mit Speziallabor ZOTZ | KLIMAS
Weitere Kooperation mit zertifiziertem Speziallabor Mehr Informationen für individuelle Therapien Read More
Agendia to Provide First Digital MammaPrint Capability to Brazil
AI solution will expand Agendia’s testing platform in the Brazilian Read More
Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care
Multi-year partnership to advance the use of next-generation sequencing for Read More
Agendia Appoints Suja Chandrasekaran and Scott Mendel to Board of Directors, Strengthening Advisory Group to Support Company Momentum
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – January 6, 2022 Read More
Agendia Spotlight Poster at SABCS 2021 Confirms Utility of BluePrint as Biomarker Subtyping Test to Guide Neoadjuvant Chemotherapy Decisions
Additional research from the real-world FLEX Registry focuses on age Read More
